Neuro-Oncology: The Podcast
By Neuro-Oncology
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by Neuro-Oncology
Category: Medicine
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 9
Reviews: 0
Episodes: 79
Description
Neuro-Oncology: The Podcast will keep you up to date about the latest advances in the field as we present conversations with the authors of selected papers from Neuro-Oncology and its sister journals, Neuro-Oncology Practice and Neuro-Oncology Advances.
| Episode | Date |
|---|---|
|
Long-term outcomes of pediatric patients with optic pathway glioma
|
May 04, 2024 |
|
NF1 mutation and neuronal hyperexcitability
|
Apr 12, 2024 |
|
Postoperative cerebellar mutism
|
Apr 05, 2024 |
|
Cell cycle checkpoints and alkylating agents
|
Mar 22, 2024 |
|
Liquid biopsy in CNS lymphoma
|
Mar 15, 2024 |
|
Immunotherapy for glioblastoma, lessons learned
|
Mar 08, 2024 |
|
TERTp mutation clonality in glioma
|
Feb 27, 2024 |
|
Liquid biopsy in H3K27M glioma
|
Feb 09, 2024 |
|
Glioma genetic profiles and electrophysiologic hyperexcitability
|
Jan 26, 2024 |
|
Epidemiology of glioma in Belgium
|
Jan 12, 2024 |
|
The Biology of H3K27M Mutant Gliomas
|
Dec 23, 2023 |
|
3D tumor volume assessment in PCNSL
|
Dec 01, 2023 |
|
Brain-tumor related epilepsy; a SNO consensus review
|
Nov 17, 2023 |
|
Vorasidenib and grading of IDH mutant astrocytoma
|
Oct 27, 2023 |
|
Insulin feedback and PI3K inhibition in GBM
|
Oct 06, 2023 |
|
SOX10 indel mutations in schwannomas
|
Sep 22, 2023 |
|
Dendritic cell vaccines in gliomas
|
Sep 08, 2023 |
|
Intrathecal trastuzumab for leptomeningeal metastases
|
Aug 11, 2023 |
|
Short term topiramate for radiation induced cytotoxic edema
|
Jul 21, 2023 |
|
Venous thromboembolism in gliomas
|
Jul 08, 2023 |
|
RANO resect
|
Jun 23, 2023 |
|
Methylation profiling of adult ependymoma
|
Jun 09, 2023 |
|
Pseudoprogression in IDH-mutant high-grade gliomas
|
May 12, 2023 |
|
Changes in survival outcomes in melanoma patients with brain metastases
|
Apr 21, 2023 |
|
Radiation therapy and structural brain changes
|
Apr 07, 2023 |
|
Objective response rate targets for recurrent glioblastoma clinical trials
|
Mar 17, 2023 |
|
Mitotic count prognostic significance in IDH-mutant astrocytoma in the molecular era
|
Mar 03, 2023 |
|
Palliative care in neuro-oncology
|
Feb 10, 2023 |
|
Nivolumab in MGMT methylated GBM
|
Jan 27, 2023 |
|
IDH mutant gliomas; SNO consensus Review
|
Jan 13, 2023 |
|
DNA methylation subclass and extent of GBM resection
|
Dec 30, 2022 |
|
Pre-operative [11C]methionine PET for low-grade glioma
|
Dec 16, 2022 |
|
The role of T lymphocytes in the glioma pathobiology
|
Dec 02, 2022 |
|
CDKN2A homozygous deletion in IDH mutant astrocytoma
|
Oct 08, 2022 |
|
EGFR: the lazarus target in glioblastom
|
Sep 23, 2022 |
|
Brain metastases; a SNO consensus review: Part 2
|
Sep 09, 2022 |
|
Brain metastases; a SNO consensus review: Part 1
|
Aug 26, 2022 |
|
Pediatric IDH mutant gliomas
|
Aug 13, 2022 |
|
Low-risk meningioma: Outcomes from NRG 0539
|
Jul 29, 2022 |
|
Selumetinib in children with NF1 and plexiform neurofibroma
|
Jul 01, 2022 |
|
Targeted therapy for BRAF-mutant pediatric glioma
|
Jun 17, 2022 |
|
Early/evolving IDH wild-type glioblastoma
|
May 20, 2022 |
|
PI3K signaling in IDH mutant gliomas
|
May 06, 2022 |
|
Cell-free DNA from CSF in pediatric, adolescent and young adult patients
|
Apr 22, 2022 |
|
Molecular determinants of neurocognitive deficits in glioma
|
Apr 08, 2022 |
|
H3K27M cell-free tumor DNA tracking in response to ONC201 treatment for diffuse midline glioma
|
Mar 25, 2022 |
|
Clinical trial accrual for women and minorities in neuro-oncology
|
Mar 11, 2022 |
|
The clinical utility of next generation sequencing for IDHwt glioblastoma
|
Feb 11, 2022 |
|
Trabectedin for recurrent grade 2 or 3 meningiomas
|
Jan 28, 2022 |
|
Glioblastoma cell heterogeneity and plasticity
|
Jan 14, 2022 |
|
Moleculary integrated grading for meningioma
|
Dec 24, 2021 |
|
BOLD fMRI in IDH mutant gliomas
|
Dec 10, 2021 |
|
Glioblastoma subtypes and response to Dasatinib
|
Nov 26, 2021 |
|
Resection for recurrent brain metastases
|
Nov 12, 2021 |
|
Incidental Meningiomas
|
Oct 29, 2021 |
|
Immunosuppression in IDH mutant gliomas
|
Oct 15, 2021 |
|
Immunotherapy for melanoma brain metastases
|
Oct 01, 2021 |
|
DNA methylation profiles within the CATNON trial
|
Sep 17, 2021 |
|
18F FET PET in childhood CNS tumors
|
Sep 03, 2021 |
|
Checkpoint blockade in atypical meningiomas
|
Aug 20, 2021 |
|
Molecular signatures of glioma causation
|
Aug 06, 2021 |
|
Testing methods for MGMT promoter methylation
|
Jul 23, 2021 |
|
Temozolomide-induced hypermutation in IDH-mutant low-grade gliomas
|
Jul 09, 2021 |
|
Posterior fossa syndrome
|
Jun 18, 2021 |
|
Loss of H3K27me3 in meningiomas
|
Jun 04, 2021 |
|
Loss of H3K27me3 in the Tübingen meningioma cohort
|
May 21, 2021 |
|
A prospective phase II randomized trial of proton radiotherapy vs intensity modulated radiotherapy for patients with newly diagnosed GBM
|
May 07, 2021 |
|
Brain radiotherapy and decline in fine motor skills
|
Apr 09, 2021 |
|
A serum based DNA methylation assay to detect gliomas
|
Mar 26, 2021 |
|
PTEN deficiency and proteosome addiction in glioblastoma
|
Mar 12, 2021 |
|
Cold-Inducible RNA-Binding Protein expression and recurrence of brain metastases
|
Feb 26, 2021 |
|
The incidence of brain metastases among patients with metastatic breast cancer
|
Feb 12, 2021 |
|
Epidemiology of Brainstem High-Grade Gliomas in Children and Adolescents in the United States, 2000-2017
|
Jan 29, 2021 |
|
A large longitudinal study of patients with Neurofibromatosis Type 2.
|
Jan 15, 2021 |
|
Vorinostat and bevacizumab for recurrent glioblastoma
|
Jan 01, 2021 |
|
A subset of pediatric thalamic gliomas
|
Dec 18, 2020 |
|
Supratotal resection of lower-grade gliomas
|
Dec 04, 2020 |
|
Friends of SNO
|
Nov 20, 2020 |
|
Announcing Neuro-Oncology: The Podcast
|
Nov 19, 2020 |